XBiome and Yuansheng Bio Announce Strategic Partnership in Probiotics Sector
Xbiome
AI Drug Developer for Gut Microbiota
2024Year9Month4On [date], Xbiome Co. Ltd. ("Xbiome") and Yuansheng Biotechnology Co. Ltd. ("Yuansheng Biotech") officially signed a strategic cooperation agreement in Ningbo.Announce the establishment of a long-term strategic partnership to engage in an all-around exclusive and in-depth cooperation in the industrialization of probiotics.The two parties are naturally complementary and pursue win-win cooperation, jointly promoting industrial innovation and sustainable, healthy development in the industry. Xbiome Co. Ltd.,CEODr. Tan Yan and Ms. Zhu Jiaolin, Chairwoman of Yuansheng Bio, attended the signing ceremony together.
According to the cooperation agreement, Xbiome and YBS Bio will fully utilize their respective technical and R&D advantages to collaborate in multiple areas such as the development of probiotic strains, optimization of production processes, efficacy validation, and market promotion, committing to the development.More Authoritative Scientific Validation、More Rigorous Evidence-Based Research on Effectiveness, Probiotic products with higher added value.
At the signing ceremony,Xbiome Co. Ltd. Co-Founder and CEO, Dr. Tan YanIndicates,It is a great honor to become a long-term strategic partner with Yuansheng Biotechnology.The human intestinal micro-ecology is emerging as a vast blue ocean market encompassing pharmaceuticals, healthcare, and consumer goods. Xbiome's AI microbiome research and industrial transformation platform is capable of meeting the high demand for probiotics from the market and partners through rigorous scientific evidence-based research.Yuansheng Biotech's continuous investment in high-end equipment over the years, along with its strict control over processes and quality, is admirable and has laid a solid foundation for our cooperation. We look forward to working together to continuously produce high-quality probiotic products.
Ms. Zhu Jiaolin, Chairwoman of Yuansheng BiotechnologyWe are very much looking forward to collaborating with Xbiome. Yuansheng Biotechnology is a highly tech-driven enterprise, established with the aim of creating a full industrial chain of probiotics adhering to high-quality manufacturing standards. We have always prioritized quality, firmly advanced technological cost reduction and efficiency enhancement, strictly followed production process discipline, and committed to producing genuinely market-proven high-quality products. Our goal is to become a premium manufacturing supply chain in the probiotics industry. Xbiome possesses China's leading AI microbiome research and industrial transformation platform, as well as strong clinical research capabilities. We believe this collaboration represents another significant milestone in the industry, jointly promoting the high-quality development of gut microbiota and the probiotics sector.
Both parties unanimously believe that the strategic cooperation between Xbiome and Yuansheng Bio will further enhance their core competitiveness in the probiotics industry, and will also provide strong support for promoting the innovation and industrial application of probiotics technology.It is reported that the first probiotic new product jointly developed by the two parties will be officially released soon. The innovative formula of this product is based on Xbiome's patented strains, showcasing Xbiome's clinical research capabilities in gut microbiota and Yuansheng Biotechnology's pharmaceutical-grade manufacturing standards to the market.FutureBoth parties will continue to uphold the concept of win-win cooperation, move forward hand in hand, and jointly write a new chapter in the probiotics industry.
| Yuansheng Biotechnology Co., Ltd.
Yuansheng Biotechnology Co., Ltd. and its wholly-owned subsidiary, Qiansheng (Ningbo) Technology Co., Ltd., focus on the high-standard manufacturing of probiotics and customized research, production, and sales of their functional applications. The company is committed to building a full industrial chain from the screening of probiotic strains, optimization of production processes, efficacy research, to the development and application of compatibility formulas. The Ningbo production base covers an area of over 52,000 square meters, with 100,000 square meters of factory space and more than 10,000 square meters of Class 100,000 cleanrooms. It is equipped with two fully automatic intelligent production lines, with the first phase of annual production capacity reaching 600 tons of bacterial powder and 1 billion sachets. Over the past decade, the company has dedicated itself to fundamental technology research and introduced a U.S. pharmaceutical research team for innovative development. The first phase invested 50 million yuan in constructing a professional research and experimental center covering more than 3,700 square meters. Yuansheng Biotechnology aims to become a core supply chain for global functional probiotic raw powders and a leader in customized global probiotic applications.
| Xbiome Co. Ltd.
Xbiome Co. Ltd., founded in 2017, owns a leading AI microbiome research and industrial transformation platform, strategically focusing on FMT (fecal microbiota transplantation), drug discovery, and probiotics. In drug discovery, the team has completed layouts in areas such as oncology, digestive diseases, immune-related diseases, and urinary system diseases, with four pipelines now in clinical stages, two of which have entered phase II clinical trials. In FMT, Xbiome has collaborated with nearly 20 well-known tertiary hospitals in China, including Peking University Cancer Hospital and Peking Union Medical College Hospital, to conduct gut microbiome clinical research across various indications. It has also developed precision microbiota transplantation solutions targeting the broader health market to benefit patients with chronic diseases and sub-health populations. In the field of probiotics, Xbiome has...Yuansheng Bio, etc.Major health companies in China and abroad have completed commercial cooperation and transformation, while continuously advancing the development of proprietary strains. In the 2024 list of "Future Stars" featuring 21 high-growth innovative companies published by *Entrepreneur China*, Xbiome was selected as a representative enterprise in the biopharmaceutical industry.
-End-